Denis Bergeron, PhD

Radiopharmaceuticals, Theranostics, and Nuclear Medicine

We present advancements of single-molecule biodosimetry to measure radiation-induced DNA damage from α-emitting 225Ac. These results will be compared to β-emitting radionuclides to assess relative biological effectiveness (RBE) for radionuclide therapies.

With advances in Targeted Alpha Therapy (TAT) preclinical and clinical research, the importance for accurate and traceable dosimetry with sub-organ resolution becomes critical. Current limitations in verifying imaging resolution and activity quantification hi...